 fusion+ metastatic non–ؘsmall-cell lung cancer and insights on approaching testing for 

Data from the following clinical trials are discussed:

Selpercatinib (LOXO-292) in patients with 

-fusion+ non–small cell lung cancer. (Goto K et al. 2020 ASCO annual meeting. Abstract 3584.)

Intracranial activity of selpercatinib (LOXO-292) in 

 fusion-positive non–small cell lung cancer patients on the LIBRETTO-001 trial. (Subbiah V et al. 2020 ASCO annual meeting. Abstract 9516.)

Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients with advanced 

 fusion+ non–small cell lung cancer. (Gainor JF et al. 2020 ASCO annual meeting. Abstract 9515.)

RET Fusion+ mNSCLC

A discussion on the FDA approved treatment option, capmatinib, and FDA breakthrough therapy designation, tepotinib, for treatment of mNSCLC with 

-amplified advanced non–small cell lung cancer: results from cohort 6 of the phase 2 GEOMETRY mono-1 study. (Groen HJM et al. 2020 ASCO annual meeting. Abstract 9520.)

Tepotinib in non–small cell lung cancer with 

exon 14 skipping mutations. (Paik PK et al. 

MET Exon 14 Mutations in mNSCLC

Detecting HER2 expression by IHC in lung cancer, the role of ADCs in targeting 

mutations, and the FDA breakthrough designation for trastuzumab deruxtecan are examined.

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with 

-mutated metastatic non–small cell lung cancer: Interim results of DESTINY-Lung01. (Smit EF et al. 2020 ASCO annual meeting. Abstract 9504.)

HER2 Targeted Therapy for Treatment of NSCLC

 mutations and incorporating AMG 510 and MRTX849 into clinical practice when treating mNSCLC.

KRAS-Mutant NSCLC

Thoracic oncologists evaluate emerging data presented at the ASCO 2020 virtual meeting on agents for the treatment of 

ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with 

exon 20 insertions. (Piotrowska Z et al. 2020 ASCO annual meeting. Abstract 9513.)

Poziotinib shows activity and durability of responses in subgroups of previously treated 

exon 20 NSCLC patients. (Le X at al. 2020 ASCO annual meeting. Abstract 9514.)

Amivantamab (JNJ-61186372), an anti–EGFR-MET bispecific antibody, in patients with 

exon 20 insertion-mutated non–small cell lung cancer. (Park K et al. 2020 ASCO annual meeting. Abstract 9512.)

EGFR Exon 20 Mutations in NSCLC

A review of new FDA approvals in I/O therapy regarding a nivolumab/ipilimumab-based regimen as seen in the CheckMate 227 and CheckMate 9LA studies, along with considerations for immune-related adverse events.

CheckMate 227: Nivolumab plus ipilimumab in advanced non–small cell lung cancer (Hellmann MD et al. 

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non–small cell lung cancer: Three-year update from CheckMate 227 Part 1. (Ramalingam SS et al. 2020 ASCO annual meeting. Abstract 9500.)

Nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy vs 4 cycles chemo as first-line treatment for stage IV/recurrent non–small cell lung cancer: CheckMate 9LA. (Reck M et al. 2020 ASCO annual meeting. Abstract 9501.)

IMpower110: Clinical safety in a phase III study of atezolizumab monotherapy vs platinum-based chemotherapy in first-line non–small cell lung cancer. (Jassem J et al. 2020 ASCO annual meeting. Abstract e21623.)

“Lung Cancer Talk”: A Review of Data from the ASCO 2020 Virtual Meeting | The Talk

EP 1: RET Fusion+ mNSCLC

EP 2: MET Exon 14 Mutations in mNSCLC

EP 3: HER2 Targeted Therapy for Treatment of NSCLC

EP 4: KRAS-Mutant NSCLC

EP 5: EGFR Exon 20 Mutations in NSCLC

EP 6: Updates on I/O Therapy for Non-Driver mNSCLC